anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Quote

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 18,554
Current window 12,271-12,300
Pages 619
Rows per page 30
Component: Quoteclear collectionreset all
18 30 60

Component

12,271-12,300 of 18,554

filter-aware
09
Uses a direct quote from financial statements to highlight a contradiction in disclosure practices.CPI Property Group (CPIPGR) · Muddy Waters Research
Activist deck Short seller Beat · Expose Contradiction1 hit
04
This slide serves as a critique of clinical trial design and reporting practices, specifically regarding the SONAR trial.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The Monster1 hit
06
The slide uses data from the RADAR trial to challenge the validity of UACR as a reliable surrogate endpoint for kidney function.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
09
The slide uses Kaplan-Meier survival curves to illustrate the convergence of outcomes between placebo and Atrasentan groups.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
11
The slide functions as a critique of clinical trial data integrity, specifically focusing on the inclusion of serum creatinine doubling and the use of inulin as a gold standard.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
12
The slide uses bar charts to show baseline vs treatment effects on GFR, ERBF, EFF, and ERVR, suggesting these metrics are influenced by blood dilution.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
13
The slide uses a table to highlight discrepancies in mortality reporting between the 'Enrichment' group and the 'Double-Blind' groups.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
14
Includes references to clinical trial data and expert commentary regarding cardiovascular and renal side effects of atrasentan.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
21
The slide uses a callout box for trial results and follows with a critical analysis of anemia as a side effect.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
22
Includes extensive footnotes citing regulatory documents and investor call transcripts.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
24
This is a text-heavy research note page focusing on competitive critique and data skepticism.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
28
The text focuses on statistical manipulation in clinical trial endpoints and discrepancies in patient count reporting between AFFINITY and ALIGN studies.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The VictoryLoop · Cost Of Inaction1 hit
29
The slide uses a 'villain critique' approach to undermine the credibility of the company's clinical trial reporting.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The VictoryLoop · Cost Of Inaction1 hit
32
Figure from SONAR trial report.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The VictoryLoop · Cost Of Inaction1 hit
33
Poster format including background, baseline/safety data, efficacy results, and conclusions.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The VictoryLoop · Cost Of Inaction1 hit
34
Includes detailed diagrams of disease pathophysiology and clinical trial design.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
35
The slide displays a forest plot comparing eGFR decline rates between atrasentan and placebo groups, segmented by pre-trial eGFR slope, UACR, and baseline eGFR.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
36
Data source identified as FDA SONAR data.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
03
This slide functions as a forensic accounting critique, highlighting specific instances of alleged financial misreporting.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The MonsterLoop · The Reveal1 hit
04
This is a text-heavy research note page focusing on accounting irregularities and investor behavior.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · The Reveal1 hit
05
The slide uses forensic accounting analysis to challenge the legitimacy of reported revenue and the operational substance of the SanReno joint venture.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · The Reveal1 hit
07
The slide details specific accounting irregularities regarding warrant valuation and cost reimbursements, supported by extensive footnotes referencing SEC filings.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Loop · The Reveal1 hit
08
The slide argues that certain revenue should be reported as net rather than gross, citing specific 10-K filings.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Loop · The Reveal1 hit
10
The slide highlights a discrepancy in accounting treatment between two joint ventures to suggest financial manipulation.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The VictoryLoop · Cost Of Inaction1 hit
37
The slide uses a narrative structure to expose financial complexity and potential fraud, referencing specific entities and dates.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Victory1 hit
03
Uses hyperbolic language ('gulags') and external citation (The Guardian) to frame the property negatively.Vivion Investments · Carson Block
Research note Short seller 1 hit
04
The slide uses a news headline as a hook to introduce a valuation discrepancy argument.Vivion Investments · Carson Block
Research note Short seller Beat · Thesis Headline1 hit
06
The slide highlights a discrepancy in valuation for the Crowne Plaza London Heathrow asset between two different sources (Vivion vs CBRE).Vivion Investments · Carson Block
Research note Short seller Beat · Appendix Data1 hit
02
This is a research note from Muddy Waters Research, acting as an activist short report.Sunrun Inc. (RUN) · Carson Block
Research note Short seller Beat · Problem & ComplicationLoop · Aha Moment1 hit
09
The table includes specific exclusions/inclusions for Vivint Solar in early periods.Sunrun Inc. (RUN) · Muddy Waters Research
Activist deck Short seller 1 hit